134 related articles for article (PubMed ID: 29479820)
1. Erythrocyte-Derived Nanoparticles as a Theranostic Agent for Near-Infrared Fluorescence Imaging and Thrombolysis of Blood Clots.
Vankayala R; Corber SR; Mac JT; Rao MP; Shafie M; Anvari B
Macromol Biosci; 2018 Apr; 18(4):e1700379. PubMed ID: 29479820
[TBL] [Abstract][Full Text] [Related]
2. Thrombus-specific theranostic nanocomposite for codelivery of thrombolytic drug, algae-derived anticoagulant and NIR fluorescent contrast agent.
Chang LH; Chuang EY; Cheng TM; Lin C; Shih CM; Wu AT; Jheng PR; Lu HY; Shih CC; Mi FL
Acta Biomater; 2021 Oct; 134():686-701. PubMed ID: 34358695
[TBL] [Abstract][Full Text] [Related]
3. Preparation of Peptide and Recombinant Tissue Plasminogen Activator Conjugated Poly(Lactic-Co-Glycolic Acid) (PLGA) Magnetic Nanoparticles for Dual Targeted Thrombolytic Therapy.
Chen HA; Ma YH; Hsu TY; Chen JP
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32294917
[TBL] [Abstract][Full Text] [Related]
4. Erythrocyte-Inspired Discoidal Polymeric Nanoconstructs Carrying Tissue Plasminogen Activator for the Enhanced Lysis of Blood Clots.
Colasuonno M; Palange AL; Aid R; Ferreira M; Mollica H; Palomba R; Emdin M; Del Sette M; Chauvierre C; Letourneur D; Decuzzi P
ACS Nano; 2018 Dec; 12(12):12224-12237. PubMed ID: 30427660
[TBL] [Abstract][Full Text] [Related]
5. Erythrocyte-Derived Theranostic Nanoplatforms for Near Infrared Fluorescence Imaging and Photodestruction of Tumors.
Burns JM; Vankayala R; Mac JT; Anvari B
ACS Appl Mater Interfaces; 2018 Aug; 10(33):27621-27630. PubMed ID: 30036031
[TBL] [Abstract][Full Text] [Related]
6. Targeted nano-delivery strategies for facilitating thrombolysis treatment in ischemic stroke.
Ma H; Jiang Z; Xu J; Liu J; Guo ZN
Drug Deliv; 2021 Dec; 28(1):357-371. PubMed ID: 33517820
[TBL] [Abstract][Full Text] [Related]
7. Tissue Plasminogen Activator-Porous Magnetic Microrods for Targeted Thrombolytic Therapy after Ischemic Stroke.
Hu J; Huang S; Zhu L; Huang W; Zhao Y; Jin K; ZhuGe Q
ACS Appl Mater Interfaces; 2018 Oct; 10(39):32988-32997. PubMed ID: 30192506
[TBL] [Abstract][Full Text] [Related]
8. Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis.
Marsh JN; Senpan A; Hu G; Scott MJ; Gaffney PJ; Wickline SA; Lanza GM
Nanomedicine (Lond); 2007 Aug; 2(4):533-43. PubMed ID: 17716136
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapeutic drug-photothermal agent co-self-assembling nanoparticles for near-infrared fluorescence and photoacoustic dual-modal imaging-guided chemo-photothermal synergistic therapy.
Li Y; Liu G; Ma J; Lin J; Lin H; Su G; Chen D; Ye S; Chen X; Zhu X; Hou Z
J Control Release; 2017 Jul; 258():95-107. PubMed ID: 28501673
[TBL] [Abstract][Full Text] [Related]
10. Ultrasound-facilitated thrombolysis using tissue-plasminogen activator-loaded echogenic liposomes.
Tiukinhoy-Laing SD; Huang S; Klegerman M; Holland CK; McPherson DD
Thromb Res; 2007; 119(6):777-84. PubMed ID: 16887172
[TBL] [Abstract][Full Text] [Related]
11. Novel and emerging therapies: thrombus-targeted fibrinolysis.
Lippi G; Mattiuzzi C; Favaloro EJ
Semin Thromb Hemost; 2013 Feb; 39(1):48-58. PubMed ID: 23034825
[TBL] [Abstract][Full Text] [Related]
12. Bioresponsive Polyphenol-Based Nanoparticles as Thrombolytic Drug Carriers.
Yu H; Palazzolo JS; Zhou J; Hu Y; Niego B; Pan S; Ju Y; Wang TY; Lin Z; Hagemeyer CE; Caruso F
ACS Appl Mater Interfaces; 2022 Jan; 14(3):3740-3751. PubMed ID: 35019268
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activation and thrombolysis for ischemic stroke.
Medcalf RL; Davis SM
Int J Stroke; 2012 Jul; 7(5):419-25. PubMed ID: 22463085
[TBL] [Abstract][Full Text] [Related]
14. Sonothrombolysis is effective with recombinant tissue-type plasminogen activator, but not with Abciximab. Results from an in vitro study with whole blood clots and platelet-rich clots.
Eggers J; Ossadnik S; Hütten H; Seidel G
Thromb Haemost; 2009 Dec; 102(6):1274-7. PubMed ID: 19967161
[TBL] [Abstract][Full Text] [Related]
15. Prussian blue/serum albumin/indocyanine green as a multifunctional nanotheranostic agent for bimodal imaging guided laser mediated combinatorial phototherapy.
Sahu A; Lee JH; Lee HG; Jeong YY; Tae G
J Control Release; 2016 Aug; 236():90-9. PubMed ID: 27349352
[TBL] [Abstract][Full Text] [Related]
16. A new drug delivery system for intravenous coronary thrombolysis with thrombus targeting and stealth activity recoverable by ultrasound.
Kawata H; Uesugi Y; Soeda T; Takemoto Y; Sung JH; Umaki K; Kato K; Ogiwara K; Nogami K; Ishigami K; Horii M; Uemura S; Shima M; Tabata Y; Saito Y
J Am Coll Cardiol; 2012 Dec; 60(24):2550-7. PubMed ID: 23158532
[TBL] [Abstract][Full Text] [Related]
17. Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic.
Yepes M; Roussel BD; Ali C; Vivien D
Trends Neurosci; 2009 Jan; 32(1):48-55. PubMed ID: 18963068
[TBL] [Abstract][Full Text] [Related]
18. Effects of tissue plasminogen activator timing on blood-brain barrier permeability and hemorrhagic transformation in rats with transient ischemic stroke.
Zhang Y; Wang Y; Zuo Z; Wang Z; Roy J; Hou Q; Tong E; Hoffmann A; Sperberg E; Bredno J; Berr SS; Xie M; Lee K; Wintermark M
J Neurol Sci; 2014 Dec; 347(1-2):148-54. PubMed ID: 25292413
[TBL] [Abstract][Full Text] [Related]
19. Targeted delivery of tissue plasminogen activator by binding to silica-coated magnetic nanoparticle.
Chen JP; Yang PC; Ma YH; Tu SJ; Lu YJ
Int J Nanomedicine; 2012; 7():5137-49. PubMed ID: 23055726
[TBL] [Abstract][Full Text] [Related]
20. Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke.
Ning M; Furie KL; Koroshetz WJ; Lee H; Barron M; Lederer M; Wang X; Zhu M; Sorensen AG; Lo EH; Kelly PJ
Neurology; 2006 May; 66(10):1550-5. PubMed ID: 16717217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
